Breast cancer is a genetic disease arising from a series of germ-line and/or somatic DNA changes in a variety of genes, including BRCA1 and BRCA2. DNA modi®ca-tions have been shown to occur by a number of mechanisms that include DNA methylation. In some cases, the aberrant methylation of CpGs within 5' regulatory regions has led to suppression of gene activity. In this report we describe a variation in the pattern of DNA methylation within the regulatory region of the BRCA1 gene. We found no evidence of methylation at CpGs within the BRCA1 promoter in a variety of normal human tissues. However, screening of a series of randomly sampled breast carcinomas revealed the presence of CpG methylation adjacent to the BRCA1 transcription start site. One such methylated CpG occurs at a putative CREB (cAMP-responsive element binding) transcription factor binding site in the BRCA1 promoter. Gelshift assays with methylated and unmethylated BRCA1/CREB binding site oligonucleotides demonstrate that this site is sensitive to site-speci®c CpG methylation. These data suggest that aberrant DNA methylation at regulatory sequences in the BRCA1 locus may play a role in the transcriptional inactivation of the BRCA1 gene within subclones of breast tumors. This study represents the ®rst evidence suggesting a role for DNA methylation in the transcriptional inactivation of the BRCA1 in human breast cancer.
Introduction
Breast cancer is one of the most common malignancies and causes of death among women in Western industrialized society. Although the majority of these cancers are the result of somatic mutations, epidemiological data indicates that 5 ± 10% of all breast cancers are associated with inherited mutations in the autosomal tumor suppressor susceptibility genes BRCA1 and BRCA2 (Newman et al., 1988; Claus et al., 1991) . The breast and ovarian cancer susceptibility (BRCA1) gene was the ®rst of these tumor suppressor genes to be characterized (Miki et al., 1994; ShattuckEidens et al., 1995) . BRCA1 mutations are responsible for nearly half of inherited breast cancers, over 80% of inherited ovarian cancers, a threefold increased risk of prostate cancer in males, and a fourfold increased risk of colon cancer in men and women (Ford et al., 1994; Szabo and King, 1995) .
DNA methylation plays two important roles in the progression of human cancers and is one of the processes through which germline and somatic DNA sequence changes can occur (Laird and Jaenisch, 1994; Jones, 1996) . First, DNA methylation is a signi®cant contributor of point mutations at CpG dinucleotides (CpGs) in a variety of growth regulatory genes. This results from the increased mutability of 5-methylcytosine ( m5 C), which is prone to transitional mutations (i.e. C?T or G?A changes) by deamination at CpGs. As a consequence, CpGs behave as hotspots for mutations in a variety of genes. For example, exons 5 ± 8 in the p53 gene have been shown to be completely methylated at all CpGs, most of which are sites for reported mutations in a variety of tumors (Tornaletti and Pfeifer, 1995) . As well, in our laboratory we have shown that coding region CpGs within the BRCA1, retinoblastoma (RB1) and neuro®bromatosis (NF1) genes are constitutively methylated, including those at recurrent mutation sites Mancini et al., 1997; Rodenhiser et al., 1996) . It is therefore clear that DNA methylation at CpG dinucleotides predisposes genes to transitional mutations, particularly those resulting in a premature termination of protein translation that appear to be selected for in the clinically expressed phenotype .
Second, DNA methylation can play a dramatic role in suppressing gene expression through aberrant methylation of CpGs within 5' gene regulatory regions. In contrast to most of the genome where CpGs are few in number but are consistently methylated, CpG islands are usually unmethylated (Laird and Jaenisch, 1994) and are a potential site for gene regulation via DNA methylation (Issa et al., 1996a,b; Lapidus et al., 1996; Ohtani-Fujita et al., 1993; Ottaviano et al., 1994) . Hypermethylation of CpG islands has been shown to alter gene expression, thereby providing one of the mechanisms of tumor suppressor gene inactivation that contributes to the initiation and progression of human cancers. However, a role for methylation-mediated gene inactivation of the BRCA1 gene in familial and sporadic breast cancer has yet to be investigated.
In this report we describe evidence of aberrant DNA methylation within the regulatory region of the BRCA1 gene in tumor tissue DNA. While we found no evidence of methylation at CpGs within the BRCA1 promoter in a variety of normal human tissues, our screening of 11 randomly sampled breast and ovarian carcinomas has revealed that clone-speci®c DNA methylation occurs in the regulatory region which anks BRCA1 exon 1A. Furthermore, DNA methylation occurs at putative transcription factor binding sites in the BRCA1 promoter, including at an apparent CREB (cAMP-responsive element binding) motif that gel mobility shift assays show to be sensitive to sitespeci®c CpG methylation. These data suggest that aberrant DNA methylation at BRCA1 regulatory sequences plays a role in the genetic heterogeneity of breast cancer.
Results
Our strategy for this study was (a) to isolate DNA from a variety of banked normal tissues and several representative sporadic breast tumors; (b) to convert these DNA samples using the sodium bisul®te protocol; (c) to amplify speci®c regions of the BRCA1 5' coding and regulatory regions by PCR, and then (d) to clone and sequence representative clones of these PCR products to develop a methylation map in the region of the BRCA1 transcription start site (Figure 1) . In some cases, DNA methylation occurred at putative transcription factor binding sites. The eect of site-speci®c methylation at these putative transcription elements was then assessed (e) using gel mobility shift and competition assays.
Methylation in the BRCA1 coding region (exon 2)
We analysed a 237 bp BRCA1 sequence encompassing exon 2 that includes 30 cytosine residues. Two of these cytosines are present within CpG dinucleotide motifs, and are located at nucleotide positions 2895 and 2897 (based on the BRCA1 sequence deposited in Genbank #U37574; Figure 2 ). A total of 52 clones (each representing one of two alleles) were isolated, sequenced and analysed. We found that DNA methylation within BRCA1 exon 2 was present in all clones analysed in normal tissue, tumor tissue and the MCF-7 cell line, and that this methylation is exclusively restricted to CpG dinucleotides in this exon. Interestingly, in some experiments our primers inadvertently ampli®ed exon 2 of the BRCA1 pseudogene, as a result of sequence homologies between the pseudogene and BRCA1. Sequence dierences between the gene and pseudogene include the presence of only one CpG in the pseudogene sequence (Brown et al., 1996) . However, we found that like the BRCA1 sequence the cytosine present in the CpG dinucleotide within pseudo-exon 2 was methylated in all clones analysed, thus underscoring the consistent nature of DNA methylation in the coding regions of the BRCA1 complex.
Methylation in the BRCA1 regulatory region (exon 1A)
We analysed a 322 bp BRCA1 sequence encompassing BRCA1 exon 1A that includes 71 cytosine residues. Sixteen of these cytosines are present within CpG dinucleotide motifs, and are located at positions 1382, 1408, 1415, 1447, 1454, 1501, 1526, 1544, 1552, 1560, 1562, 1588, 1594, 1596, 1599 and 1607 (based on the BRCA1 sequence deposited in Genbank #U37574; Figure 3 ). The BRCA1 transcription start site has been previously localized to position 1582 (Xu et al., 1996) , therefore CpGs from positions 1588 ± 1607 are present within the exon 1A sequence. Unlike our previous analyses of BRCA1 exon 2, the PCR primers used in these exon 1A analyses did not inadvertently amplify the pseudogene exon 1A, due to signi®cant divergence between the two gene/pseudogene sequences (Brown et al., 1996) .
A total of 235 clones (each representing one of two alleles from the various cell lineages represented in the tumor samples) were isolated, sequenced and analysed. In 40 clones of DNAs isolated from normal tissues, we found no evidence of DNA methylation at any of the CpG dinucleotides in either exon 1A or in the gene region immediately 5' to this exon. Representative DNA sequence from one of these experiments is presented in Figure 3 . Unmethylated cytosines have been eliminated from the`C' lane of this sequence and are now accounted for in the`T' lane, due to their deamination by sodium bisul®te to uracil and subsequent PCR ampli®cation to thymidine. Furthermore, non-CpG cytosines were also found to be consistently unmethylated in the majority of clones screened and sequenced. In one placental DNA sample, a methylated cytosine at position 1444 was observed in several clones, however this result was unique to this particular tissue sample.
We also isolated, sequenced and analysed 195 clones from six anonymous breast carcinoma samples, ®ve ovarian carcinomas and a MCF-7 breast carcinoma cell line. As with the normal tissues analysed, DNA from each tumor sample was analysed by sequencing multiple clones of bisul®te-converted DNA. In contrast to DNA from normal tissues, methylation was detected in multiple clones derived from two of the breast tumor samples ( Figure  4) and two of the ovarian tumors analysed. In breast tumor #2286, ten of 33 clones exhibited DNA methylation at many of the CpGs, while the second tumor sample (#2291) exhibited CpG methylation within two of ten clones. The methylation of individual CpGs varied among individual cloned sequences (Figure 4 ). Among all methylation-positive clones analysed, DNA methylation appeared to be most often present in the CpG clusters in close proximity to the transcription start site and within the exon 1A untranslated region suggesting that methylation may more strongly exert its eect on sequence elements in close proximity to the transcription start site. Similar results were found in the ovarian tumors analysed. In all tumor material analysed, DNA methylation when present, was restricted to CpGs and no non-CpG cytosines were seen to be methylated in any clones sequenced.
Gel mobility shift and competition assays
Analysis of the BRCA1 5' UTR sequence using TFSEARCH ver. 1.3 (http://www.genome.ad.jp/SIT/ TFSEARCH.html) yielded several putative transcription factor motifs, including a CRE motif located between 155 and 179 bases upstream of the BRCA1 transcription start site. Previous reports have shown that CpG methylation within cAMP response elements abolishes CRE binding and transcriptional activation (Iguchi-Ariga and Schnaer, 1989; Comb and Goodman, 1990; Palvimo et al., 1991) . We performed experiments to determine the functional signi®cance of methylation within the BRCA1 promoter region by analysing the binding potential of methylated and unmethylated oligonucleotides (analogous to putative BRCA1 regulatory elements) to proteins within MCF-7 nuclear extracts. This BRCA1 subregion includes two closely located methylated CpGs, including one within the putative CREB motif at nucleotide position 1408. In breast tumor #2286 we found that the CpGs at positions 1408 (and 1415) were methylated in 70% (and 80%) of the methylation-positive clones, respectively, and in ovarian tumor #2613 these sites were each methylated in 50% of the methylation-positive clones ( Figure 5b ). Two double-stranded oligonucleotides were therefore synthesized and used as probes for the gel mobility shift and competition assays (see Figure 5a ). These oligos diered in the presence/ absence of methyl sidegroups at cytosines in these CpGs. Figure 5c shows the results of a gel mobility shift assay using 10 mg of MCF-7 nuclear extract and 10 5 c.p.m. (*1 pmole) of radiolabeled doublestranded oligonucleotides. Binding reactions in lanes 1 ± 7 utilized labeled unmethylated oligonucleotides; lanes 8 ± 14 utilized labeled methylated oligonucleotides. In some cases labeled oligonucleotide was run in the absence of nuclear extract and is shown in lanes 1 and 8. Lane 2 (unmethylated oligonucleotide) shows a strong signal indicating the binding of this unmethylated oligo to several proteins within the MCF-7 nuclear extract. In striking contrast, the analogous methylated oligonucleotide bound considerably less of these protein(s) (lane 9). The cross competition assays with speci®c and non-speci®c unlabeled probes show both the speci®city and sensitivity of this binding capability. For example, the presence of the protein/ unmethylated oligonucleotide complex (seen in lane 2) dramatically decreased upon addition of 50-fold (lane 3) and 250-fold (lane 4) excess of unlabeled, unmethylated oligonucleotide. In contrast, similar excess amounts of unlabeled, methylated oligonucleotide (lanes 5 and 6) did not compete with the protein/ unmethylated oligonucleotide complex. Similarly, an unrelated cathepsin D oligonucleotide failed to compete with the binding of the unmethylated DNA (lane 7). These results reinforce the ®nding of speci®city of the nuclear proteins to the unmethylated oligonucleotide. Since no binding was observed using the methylated oligo (lane 9), competition assays with all unlabeled oligos were uninformative (lanes 10 to 14). Together, these results clearly show that this putative CREB element in the BRCA1 regulatory region is exquisitively sensitive to DNA methylation. This suggests that the site-and allele-speci®c methylation in the BRCA1 regulatory region observed in breast and ovarian tumors may be functionally relevant to the normal, constitutive regulation of BRCA1 expression.
Discussion
DNA methylation plays at least two important and speci®c roles in human cancers (Laird and Jaenisch, 1994) . First, DNA methylation is a signi®cant contributor of point mutations at CpG dinucleotides in a variety of growth regulatory genes. Second, DNA methylation can play a dramatic role in suppressing gene expression through aberrant methylation of cytosine and guanine-rich gene regulatory regions called CpG islands. Both regional and locus-speci®c changes in DNA methylation can result in a selective growth advantage for a cell. These changes appear to be particularly relevant to tumor-suppressor genes such as BRCA1. We have previously reported the presence of DNA methylation within the BRCA1 coding region and its putative role in mutagenesis . However, the extent of methylation throughout the BRCA1 regulatory region and its capacity to mediate suppression of BRCA1 gene expression have not been investigated until now. Our strategy in the present study was to evaluate the methylation status of cytosines within a concise portion of the BRCA1 5' regulatory region, and to focus on sequence elements which were likely to be functionally relevant for BRCA1 transcription. Sixteen CpGs are within this putative promoter region, and each are potentially methylatable and represent possible sites for the regulation of expression of BRCA1. Several of these CpGs are located within putative transcription elements (Xu et al., 1995; see also Figure 1 ). We found no evidence of DNA methylation in the BRCA1 exon 1A region in any of the normal tissues we examined. However, DNA methylation was detected in a proportion of the breast tumor and ovarian tumor samples we have screened. This novel pattern of DNA methylation was variable both with respect to its presence at individual CpG sites and between individual clones. We were able to discern these clone-speci®c patterns of methylation using the sodium bisul®te conversion method to identify methylation in the BRCA1 regulatory region. This method provides advantages over earlier techniques Lanes 1 ± 7 labeled unmethylated oligo; lanes 8 ± 14 labeled methylated oligo. Lanes 1 and 8: free probe (no extract added). Lanes 2 ± 7 and 9 ± 14: oligos incubated with the nuclear extracts followed by the addition of excess amounts of unlabeled, unmethylated oligo (lanes 3, 4, 12, 13), unlabeled methylated oligo (lanes 5, 6, 10, 11) or an unlabeled, non-competing cathepsin D oligo (7, 14) . The complexes were run on a 8% non-denaturing polyacrylamide gel and exposed to autoradiograph ®lm relying on restriction enzyme digestion of template DNA prior to PCR ampli®cation since it permits allelespeci®c patterns of DNA methylation to be determined at all CpG dinucleotides within a test template, rather than being limited to the analysis of methylation at speci®c methylation-sensitive restriction enzyme sites (Merlo et al., 1995; Herman et al., 1994; Ferguson et al., 1995; Issa et al., 1996a,b) . Furthermore, the bisul®te method provided a direct analysis of DNA methylation and eliminated the possibility that incomplete digestion by methylation-sensitive restriction enzymes which would yield an inaccurate picture of DNA methylation within the test template. Our approach also ensured that we analysed only BRCA1 sequences rather than include similar sequences from the BRCA1 pseudogene.
This report of DNA methylation in the BRCA1 regulatory region supports the hypothesis that methylation contributes to tumorigenesis. For example, CpG methylation silences gene expression of at least three tumor suppressor genes. In the retinoblastoma gene (Rb), 16% of sporadic (unilateral) retinoblastoma tumors displayed hypermethylation within the 5' region of the gene, and in vitro hypermethylation at speci®c transcription factor binding sites in the Rb promoter reduces expression to only 8% of the unmethylated control (Ohtani-Fujita et al., 1993) . In the p16 tumor suppressor gene, de novo methylation of the CpG island was found in 20% of a variety of primary neoplasms, although not in normal tissues (Maesawa et al., 1996; Merlo et al., 1995) . Third, hypermethylation of a normally unmethylated CpG island in the 5' region of the von Hippel Lindau (VHL) gene silences expression in renal cell carcinoma lines (Herman et al., 1994) . Furthermore, VHL expression can be experimentally re-activated with the demethylating agent 5-aza-2'-deoxycytidine. Huang et al. (1997) identi®ed two hypermethylationcontaining fragments in ampli®ed breast tumor DNA relative to ampli®ed normal breast DNA. As well, in breast tumors and cell lines, aberrant DNA methylation has been correlated with the silencing of the estrogen receptor (ER) and progesterone receptor genes (Lapidus et al., 1996; Ohtani-Fujita et al., 1993; Ferguson et al., 1995) . While the ER CpG island was shown to be unmethylated in nine normal breast samples and 53 ER+ breast cancers, methylation was present in 25% of primary ER7 breast cancers (Lapidus et al., 1996) . Similar results were observed with the progesterone receptor (PR), since the PR CpG island is not methylated at methylation sensitive restriction sites in normal breast tissue, but is hypermethylated in 40% of PR-negative human breast tumors. It is clear that similar patterns of DNA hypermethylation are associated with a variety of tumors where ER (and PR) gene expression is suppressed, including lung tumors and cell lines (Issa et al., 1996a) and hematopoietic and leukemia cell lines (Issa et al., 1996b) .
The gel mobility shift and competition assays we present in this report provide evidence that DNA methylation may play a role in transcriptional regulation of the BRCA1 gene by impeding speci®c interactions between transcription factors (such as CREB) and their corresponding DNA control elements. Similar methylation interference studies directed at other genes have shown that CpG methylation of cAMP response elements abolishes CRE binding (Iguchi-Ariga and Schnaer, 1989; Comb and Goodman, 1990; Palvimo et al., 1991) . These results suggest a direct, site-speci®c eect of methylation on transcriptional activation. However, CpG methylation may also exert an indirect eect on the accessibility of DNA to protein factors, since the nucleosomal organization of transcription factor binding sites implies a role for chromatin structure in determining DNA accessibility (Ben-Hattar et al., 1989; Weih et al., 1991; Johnson et al., 1995) . In either case, the high density of CpGs within putative BRCA1 regulatory elements represents a considerable target at which DNA methylation can either directly or indirectly exert a functional eect (Figure 6 ). Further experiments are underway in our laboratory to determine the functional signi®cance of site-speci®c changes in methylation and the eects these changes have on BRCA1 transcriptional regulation.
Establishing a direct correlation between methylation and transcription would con®rm a functional role for this epigenetic phenomenon. Experiments to directly evaluate gene expression and DNA methylation in these paran-embedded tumor samples were not possible however, since RNA was not available from the tumor samples we analysed. In any event, correlating gene expression and DNA methylation in the context of these tissues is problematic for several reasons. First, the clonal variability in methylation we observed may indicate a multi-stage, multi-hit progression in breast tumorigenesis as hypothesized for other cancers (Eshleman and Markowitz, 1996) . In addition, a variety of small, genetically distinct tumor cell clones are likely to be present in each tumor sample, as the result of progressive genetic alterations or losses (including BRCA1 mutations) as well as aberrant patterns of methylation (epimutations in the BRCA1 promoter). These changes could include the alteration and/or transcriptional inactivation of BRCA1, and other genes critical to cell development and oncogenesis, which would then result in the tumor phenotype. The apparent association of BRCA1 (and BRCA2) with Rad51 targets the function of these gene products in DNA repair processes (Scully et al., 1997; Sharan et al., 1997) . As a consequence, predisposing mutations in these genes likely contribute to the genetic instability within these cells, with the consequence that a wide diversity of mutations and epimutations (methylation variants) will become established in subclones within the breast tumor. Recently, Kuukasjarvi and colleagues have shown that primary tumors and their asynchronous metastases are often clearly derived from the same precursor clones (Kuukasjarvi et al., 1997) . As a result, a common`progenitor' tumor clone expands and disseminates to form a family of more and more genetically distant clones that then populate the dierent tumor regions and metastatic sites (Kuukasjarvi et al., 1997) . Our data is consistent with this model, such that methylation variants in BRCA1 (and in other genes such as ER) provide an additional mechanism by which the expression of genes relevant to breast tissue function can be inactivated.
A second concern is that, at the tissue level, the clonal variations in methylation which we detected likely indicate the presence of methylated DNA from tumor cells along with unmethylated DNA from normal stromal cells. Similarly, these contaminating normal cells would also provide an additional source of BRCA1 mRNA to complicate any expression studies. Thirdly, at the cellular level, it is possible that allelespeci®c methylation within individual tumor cells contributes to this methylation mosaicism. If present, a parent-of-origin speci®c methylation eect would have interesting implications with respect to the mechanism of disease transmission and for molecular diagnosis. Taken together, these considerations rule out the possibility of establishing a clear correlation between BRCA1 gene expression in vivo and the presence of aberrant DNA methylation in these heterogeneous tumor samples. Our data do however clearly describe the presence of tumor-speci®c DNA methylation and the eect of methylation on putative transcription factor binding sites, while providing the basis to analyse site-speci®c DNA methylation using BRCA1 reporter constructs.
The speci®c eect of methylation at individual transcription factor binding sites will need to be clari®ed before the precise mechanisms of methylation-dependent inactivation of BRCA1 expression can be de®ned. A variety of environmental factors including diet, exposure to environmental carcinogens or xenoestrogens may also exert modulatory eects on constitutive patterns of DNA methylation. Furthermore, while molecular mechanisms of BRCA1 need to be fully elucidated, the potential involvement of methylation in tumorigenesis also suggests that methylation is a potential target for therapeutic intervention. This is because methylation-induced gene inactivation leaves a gene intact but suppressed, with the potential for gene reactivation by therapeutic manipulation of DNA methylation in the gene's regulatory region. Experiments are progressing to address these aspects of BRCA1 expression and to further de®ne the functional role of DNA methylation at speci®c transcription factor binding sites throughout the BRCA1 regulatory region.
Materials and methods

Sodium bisul®te protocol
Total genomic DNA was isolated (Sambrook et al., 1989) from a variety of normal human tissues (including lymphocytes, breast, placenta and muscle), tumor tissue (breast carcinomas and ovarian carcinomas), as well as from cultured ®broblasts. Lymphocyte DNA was isolated from healthy blood donors. DNA was also collected from an MCF-7 breast carcinoma cell line maintained in the laboratory of Dr Trevor Archer. To determine the methylation status of cytosines within the BRCA1 gene, DNA was modi®ed using the sodium bisul®te protocol Rodenhiser et al., 1996; Clark et al., 1994; Frommer et al., 1992) . Brie¯y, 10 mg of genomic DNA was digested with EcoRI for 6 h at 378C and subsequently denatured with fresh 1 M NaOH (®nal concentration: 0.3 M) at 378C for 15 min. The denatured template was treated with 3.6 M NaHSO 3 (pH 5), and 100 mM hydroquinone (to a ®nal concentration of 3.1 M, and 0.5 mM, respectively) and incubated at 558C for 16 h under mineral oil. This incubation included a 5 min soak period at 948C every 3 h to ensure that the template remained denatured (Clark et al., 1996; Tasheva and Roufa, 1993) . Following this treatment, the template was desalted with the Wizard DNA cleanup system (Promega) and treated with 1 M NaOH (378C for 15 min) to remove the remaining sodium bisul®te. The DNA was precipitated with 6 M ammonium acetate (pH 7) and 2 volumes of 95% ethanol, then the pellet was washed in 75% ethanol and dissolved in 50 ml double distilled H 2 O.
PCR ampli®cation and sequencing conditions
In the subsequent PCR ampli®cations, speci®c primers were constructed to amplify the sense-strand of the bisul®te-converted genomic DNA for BRCA1 exon 1A and exon 2 (Genbank accession #U37574). The primer sequences used to amplify exon 1A were: pFor1A: 5'-AAGTCGTAATTGGAAGA GTAGAGGTTAGAG -3'; pRev1A: 5'-CCACAA CCTATCCCCCATCCAAAAAAT CTC-3'. These primers ampli®ed a 322 basepair fragment (from positions 1319 to 1640) which included 16 CpGs; within the sequence upstream of the transcription start site and 5 CpGs within exon 1A. The primer sequences used to amplify exon 2 were: pFor2: 5'-TTTTATTTTAAAAT-GATGAAAATGAAGTTG-3' and pRev2: 5'-ATTTACA-TAAAAAATAATCATAAAAATCCC-3'. These primers ampli®ed a 237 basepair fragment (from positions 2778 to 3014) which included 2 CpGs. This primer pair also ampli®ed a fragment of the BRCA1 pseudogene, however the pseudogene sequences could be distinguished from BRCA1 on the basis of both size and nucleotide sequence. All PCR ampli®cations were performed in 25 ml reactions containing 50 ± 150 ng bisul®te-treated genomic DNA. The ampli®cation conditions were: 5 cycles at 948C (1 min), 608C (2 min), 728C (3 min) followed by 30 cycles at 948C (1 min), 608C (2 min), 728C (1 min). The PCR reactions were`hot-started' by adding 1 ml of the reverse primer to each of the individual samples during an intitial 948C incubation period. A ®nal 16 min soak (728C) was also performed. PCR product was cloned into the pCR II TA cloning vector (TA Cloning system; Invitrogen, San Diego, CA). Individual positive clones were identi®ed and plasmid DNAs were isolated by alkaline lysis (Sambrook et al., 1989) and sequenced with the T7 sequencing system (Pharmacia) using the forward primer .
For each tissue examined up to 36 clones were sequenced to determine the methylation status of all cytosine residues within the region analysed. The DNA sequence of bisul®te-converted template was compared with unconverted genomic DNA to allow the methylation status of all cytosines to be determined. The methylation status of each of these CpG dinucleotides was determined for every clone in all tissues. Unmethylated cytosines were characterized as those bands that were absent in the`C' lane and present in the`T' lane of the reactions from converted template. Any bands remaining in the`C' lane of the sequenced converted DNA would indicate methylated cytosines which had been subsequently ampli®ed as cytosines Rodenhiser et al., 1996; Andrews et al., 1996; Clark et al., 1994) .
Gel mobility shift and competition assays
Gel mobility shift assays were performed to characterize sequence speci®c DNA-protein interactions within the BRCA1 promoter and subsequently, to determine if this binding was altered by the presence of methylated CpGs within the oligonucleotides. Oligonucleotides for gel mobility shift assays were prepared on an Applied Biosystems 380A DNA synthesizer and puri®ed according to the manufacturer's instructions. Two pairs of complementary single-stranded oligonucleotides (one pair methylated) were annealed to generate double-stranded DNA templates for these assays. Annealing of complementary strands was performed at 958C for 15 min in 26 annealing buer (0.2 M KCl, 0.02 M Tris-HCl, pH 7.5) followed by a gradual cooling to room temperature for 1 h. These oligonucleotides corresponded to a portion in the BRCA1 regulatory region that lies between 7179 and 7155 bases upstream of the BRCA1 transcription start site (Xu et al., 1996) . Our analysis of this sequence using TFSEARCH ver. 1.3 (http://www.genome.ad.jp/SIT/TFSEARCH.html) suggested this region includes a putative cAMP responsive element (CRE) that is recognized by the methylationsensitive CREB transcription factor (Iguchi-Ariga and Schaner, 1989) . Methylated oligo-nucleotides were synthesized using 5'-dimethoxytrityl-5-methyl-2'-deoxycytidine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (Glen Research, Sterling, VA) to generate methylcytosine residues within the oligonucleotides at the two CpGs. All other non-cytosine CpGs were unmethylated. The doublestranded oligonucleotides were endlabeled with g-32 P-ATP (Amersham; 6000 Ci/mmol, 1 Ci=37 GBq) using T4 polynucleotide kinase as described previously (Archer et al., 1990 Nuclear extracts were prepared from MCF-7 cells that were washed in phosphate-buered saline and lysed on ice for 5 min in E buer (0.3% Nonidet P-40 (NP40), 10 mM Tris (pH 8.0), 60 mM NaCl, 1 mM EDTA, 1 mM dithiothrietol (DTT), 1 mM phenylmethylsulfonyl¯uoride (PMSF). Nuclei were pelleted by spinning for 5 min at 2500 r.p.m. at 48C. The pellet was washed in E buer lacking NP40 and resuspended in 100 ml of buer C (20 mM HEPES (pH 7.9) 0.75 mM spermidine, 0.15 mM spermine, 0.2 mM EDTA, 2 mM EGTA, 2 mM DTT, 20% glycerol, 1 mM PMSF). NaCl was added to a concentration of 0.4 M and the nuclei were gently shaken for 20 min at 48C prior to being pelleted by spinning for 10 min at 12 000 at 48C. The nuclear extract was stored at 7808C until use.
Competition assays compared the binding capacity of unmethylated and methylated probes alone and with an excess (506 and 2506) of unlabeled/unmethylated and unlabeled/methylated probes in separate reactions. An unrelated cathepsin D oligonucleotide was also utilized as a control in some experiments (sense: 5'-GGC CGC GCC CAC GTG ACC GGT-3'; antisense: ACC GGT CAC GTG GGC GCG GCC-3'; Wang et al., 1997) . All binding reactions contained 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 3 mM DTT, 10% glycerol, 0.05% NP40, 0.1 mM ZnCl 2 , 50 mg/ml poly (dI-dC), 10 5 c.p.m. of the double-stranded probes and 10 mg of nuclear extract from cultured MCF-7 cells. Binding proceeded at room temperature for 20 min (Archer et al., 1990) . At the end of the incubation period, the samples were separated on 5% non-denaturing polyacrylamide gels and exposed to autoradiographic ®lm for 4 h.
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